A. V. Lopatina

A. V. Lopatina

Auto-generated profile, based on publicly available information

A. V. Lopatina

Federal Center of Brain Research and Neurotechnologies of the Federal Medical and Biological Agency of Russia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
ALA.V. Lopatina
A.V. Lopatina
AKAnna Dmitrievna Kukushkina
Anna Dmitrievna Kukushkina
MMMikhail Melnikov
Mikhail Melnikov
VRVladimir S. Rogovskii
Vladimir S. Rogovskii
Рассеянный склероз (РС) — хроническое демиелинизирующее заболевание аутоиммунной природы. Терапия не всегда позволяет замедлить прогрессирование заболевания. В ряде случаев патогенетическая терапия РС приводит к серьезным побочным эффектам, в частности к иммуносупрессии, не позволяющим реализовать весь терапевтический потенциал препаратов, изменяющих течение РС (ПИТРС). В связи с этим актуально исследование потенциального применения при РС средств, обладающих иммунотропными и нейропротективными эффектами, а также благоприятным профилем безопасности. Полифенолы (соединения, содержащие фенольные и гидроксильные группы, часто природного происхождения) обладают способностью модулировать иммунорегуляторные мишени, снижая продукцию различных провоспалительных цитокинов, играющих важную роль в патогенезе РС. Совместное применение с ПИТРС веществ, обладающих благоприятным профилем безопасности и противовоспалительной активностью, а также способных проникать через гематоэнцефалический барьер, таких как полифенолы, может быть одной из перспективных стратегий при терапии РС с целью улучшения качества жизни пациентов. В данном обзоре рассматриваются механизмы действия полифенолов при РС, их применение при экспериментальных моделях РС, а также результаты клинических исследований полифенолов при РС.

23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
ALA.V. Lopatina
A.V. Lopatina
ASAnastasiya Sviridova
Anastasiya Sviridova
OBO.O. Belousova
O.O. Belousova
UKU.SH. Kuzmina
U.SH. Kuzmina
MMMikhail Melnikov
Mikhail Melnikov
Objective. To investigate the role of dopamine receptor D1DR and D2DR in the production of cytokines interleukin-6 (IL-6) and IL-1β by monocytes and macrophages in patients with relapsing-remitting multiple sclerosis (MS). Material and methods. Ten patients with relapsing-remitting MS and 10 healthy subjects were examined. The level of IL-6 and IL-1β production was assessed in culture supernatants obtained from CD14+ monocytes or macrophages stimulated with interferon-γ (IFN-γ) and lipopolysaccharide (LPS). To study the role of dopamine receptors in the regulation of CD14+ monocytes or macrophages, samples of cells were incubated in the presence of specific D1DR or D2DR antagonists, after which IFN-γ/LPS were added to the cultures. Levels of cytokines in culture supernatants were measured by enzyme-linked immunosorbent assay. Results. The production of IL-6 and IL-1β by CD14+ monocytes and macrophages was comparable between the groups. Blockade of D1DR suppressed cytokine production by CD14+ monocytes and macrophages in both groups. In contrast, blockade of D2DR increased the production of cytokines by CD14+ monocytes and did not affect cytokine production by macrophages in both groups. Conclusions. Targeting of dopaminergic receptors could be considered as an additional mechanism of immunomodulation in MS with both pro- and anti-inflammatory effects on cells of the innate immune system.

19 October 2022 in Diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
TRT. M. Rostovtseva
T. M. Rostovtseva
MDM. B. Dolgushin
M. B. Dolgushin
ALA. V. Lopatina
A. V. Lopatina
OBO. V. Boyko
O. V. Boyko
EKE. A. Kovrazhkina
E. A. Kovrazhkina
ABAlexey Boyko
Alexey Boyko
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an uncommon disease characterized by heterogeneous clinical findings, absence of specific laboratory markers and good response to treatment. Typically CIDP manifests as weakness of varying severity, from minimal paresis to plegia, as well as symmetrical loss of sensitivity in all limbs, a distinctive clinical feature of CDL is the involvement of both proximal and distal parts of extremities. At the same time, there is a large number of atypical CIDP variants, clinically similar to other chronic disimmune neuropathies. Neuroimaging findings typically include involvement of the cauda equina, brachial, and lumbar plexus. The patient sought medical help complaining of weakness and loss of sensation in the extremities. This clinical case illustrates a combined involvement of cranial and spinal nerves, as well as spinal cord and brain in a patient with chronic inflammatory demyelinating polyneuropathy.

8 August 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
RZR.R. Zhetishev
R.R. Zhetishev
ALA.V. Lopatina
A.V. Lopatina
ASAnastasiya Sviridova
Anastasiya Sviridova
MMMikhail Melnikov
Mikhail Melnikov
Objective. To systematize data on the role of monocytes in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Material and methods. Forty-six scientific publications (1990—2024) on the role of monocytes in the pathogenesis of EAE and MS were analyzed. Results. Monocytes have been found to play an essential role in both the occurrence and persistence of autoimmune neuroinflammation. They penetrate the central nervous system (CNS) through the blood-brain barrier, produce pro-inflammatory cytokines, differentiate into macrophages/dendritic cells, and activate CD4+ T-cells. The change in both quantitative and functional characteristics of monocytes in MS is described. Conclusion. Monocytes are involved in all stages of the immunopathogenesis of EAE and MS and largely mediate autoimmune demyelination in the CNS. Therefore, they can be considered a potential therapeutic target for MS.

10 August 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MMMikhail Melnikov
Mikhail Melnikov
ALA.V. Lopatina
A.V. Lopatina
ASAnastasiya Sviridova
Anastasiya Sviridova
MPM.V. Pashenkov
M.V. Pashenkov
ABAlexey Boyko
Alexey Boyko
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить влияние флуоксетина на патогенетически значимый при рассеянном склерозе (РС) Th17- и Th1-иммунный ответ. МАТЕРИАЛ И МЕТОДЫ Обследованы 10 больных ремиттирующим РС и 10 здоровых доноров. Th17- и Th1-иммунный ответ оценивали по продукции цитокинов интерлейкина-17 (ИЛ-17) и интерферона-γ (ИФН-γ) CD4+ T-клетками, активированными макрофагами или микрочастицами, покрытыми анти-CD3/CD28-антителами. Для оценки влияния флуоксетина на индуцируемый макрофагами Th17- и Th1-иммунный ответ макрофаги преинкубировали в присутствии флуоксетина и проводили ко-культивирование с аутологичными CD4+ T-клетками. В случае стимуляции CD4+ T-клеток анти-CD3/CD28-микрочастицами флуоксетин вносили непосредственно к T-хелперам перед внесением микрочастиц. Кроме того, оценивалось влияние флуоксетина на продукцию макрофагами факторов дифференцирования Th17-клеток — цитокинов ИЛ-6 и ИЛ-1β. Уровни цитокинов в супернатантах клеточной культуры измеряли методом иммуноферментного анализа. РЕЗУЛЬТАТЫ Продукция ИЛ-17 и ИФН-γ CD4+ T-клетками, стимулированными макрофагами или анти-CD3/CD28-микрочастицами, была сопоставима между группами. Продукция ИЛ-6 и ИЛ-1β макрофагами больных РС и здоровых доноров также была сопоставима. Флуоксетин подавлял выработку ИЛ-17 и ИФН-γ анти-CD3/CD28-стимулированными CD4+ T-клетками в обеих группах. Кроме того, флуоксетин подавлял продукцию ИЛ-6 и ИЛ-1β макрофагами, а также их способность индуцировать продукцию ИЛ-17 и ИФН-γ CD4+ T-клетками в обеих группах. ЗАКЛЮЧЕНИЕ Флуоксетин может оказывать противовоспалительное влияние при РС, оказывая ингибирующий эффект непосредственно на Th17- и Th1-клетки, а также на индуцируемый макрофагами Th17- и Th1-иммунный ответ.

23 August 2025 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
DND. V. Nikolaeva
D. V. Nikolaeva
RZR. R. Zhetishev
R. R. Zhetishev
ALA. V. Lopatina
A. V. Lopatina
ASAnastasiya Sviridova
Anastasiya Sviridova
DED. D. Esipova
D. D. Esipova
MMMikhail Melnikov
Mikhail Melnikov
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system (CNS) that affects young people. It has been established that CD14+ monocytes and T-helpers (CD4+ T cells) play an important role in both the development and maintenance of autoimmune neuroinflammation in MS. Noradrenaline is one of the key neurotransmitters of the CNS, which, along with regulating neuropsychological functions, also participates in the modulation of cells of the innate and adaptive immune response.Objective: to investigate the effect of noradrenaline on CD14+ monocyte-induced activation of CD4+ T cells in patients with relapsing-remitting MS.Materials and methods. A comprehensive clinical and immunological examination was conducted on 12 patients with relapsing-remitting MS and 12 healthy donors. The effect of noradrenaline on the production of interleukin 6 (IL6) and IL1 β by CD14+ monocytes, which are necessary for the differentiation of Th17 cells, as well as on the activation of the PKA–CREB signalling pathway in CD14+ monocytes, was assessed. In addition, the effect of noradrenaline on the ability of CD14+ monocytes to induce the production of IL17 and interferon γ by autologous CD4+ T cells was evaluated.Results. Noradrenaline suppressed cytokine production by CD14+ monocytes in both groups, as well as activation of the PKA–CREB signalling pathway in the group of healthy donors. Noradrenaline also suppressed the ability of CD14+ monocytes to induce IL17 production by autologous CD4+ T cells in both groups.Conclusion. Preliminary data indicate that noradrenaline has an anti-inflammatory effect in MS, which may be mediated by its influence on the function of CD14+ monocytes.